Evidence map›Paper›PMID 40352024›Full record

ReviewCureus2025

Thyroid Cancer Staging: Historical Evolution and Analysis From Macrocarcinoma to Microcarcinoma.

Carlos S Duque, Carlos E Builes-Montaño, Catalina Tobón-Ospina, Alejandro Velez Hoyos, Juan G Sánchez, Andres F Londoño, Miguel Agudelo, Julio A Valencia, Juan P Dueñas, Maria F Palacio and 1 more

Abstract readReview
In one paragraph

Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Carlos S DuqueDepartment of Surgery, Clinica Intermedica, Medellin, COL.
Carlos E Builes-MontañoDepartment of Internal Medicine, Hospital Pablo Tobón Uribe, Medellin, COL.
Catalina Tobón-OspinaDivision of Endocrinology, Diabetes, and Metabolism, Clínica Somer, Rionegro, COL.
Alejandro Velez HoyosSchool of Health Sciences, Universidad Pontificia Bolivariana, Medellin, COL.
Juan G SánchezDepartment of Surgery, Clinica (Corporación de Estudios de la Salud) CES, Medellin, COL.
Andres F LondoñoDepartment of Surgery, Hospital Pablo Tobón Uribe, Medellin, COL.
Miguel AgudeloDepartment of Hepatology, Temple University Hospital, Newark, USA.
Julio A ValenciaDepartment of Surgery, Hospital Pablo Tobón Uribe, Medellin, COL.
Juan P DueñasDepartment of Surgery, Clinica El Rosario El Tesoro, Medellin, COL.
Maria F PalacioDepartment of Surgery, Hospital Militar Central, Medellin, COL.
Natalia SierraDepartment of General Medicine, Universidad Corporación de Estudios de la Salud (CES), Medellin, COL.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The classification of thyroid cancer diagnosis and treatment has evolved dramatically since the Union for International Cancer Control (UICC) published the first staging system in 1968. A careful review of the eight published editions of well-differentiated thyroid cancer (WDTC) staging by the UICC and the American Joint Committee on Cancer (AJCC) was performed. Each edition was analyzed to clearly understand which development published and accepted by specialists treating thyroid cancer justified considering a new updated edition. This study presents a comprehensive review of the remarkable evolution of thyroid cancer staging, highlighting the various changes in several areas throughout the years and editions. There were surprising changes within the eight publications: the tumor size was progressively reduced from 4 cm in the first AJCC volume to less than 1 cm in the seventh and eighth UICC and AJCC editions, classifying these small, WDTCs known up to now as "microcarcinomas." Extrathyroidal extension was accepted after the third edition; this description certainly plays a key role in today's decisions to manage this tumor as a prognostic factor. The age specification of 45 years prevailed for seven consecutive publications until it was raised to 55 years in the eighth thyroid cancer staging system. Without a doubt, this iconic change allowed physicians around the world to give their 45-year-old thyroid cancer patients a more encouraging panorama of the disease with the new classification. Over the course of nearly 57 years, thyroid cancer staging has undergone remarkable changes, reaching a level of certainty that not only provides recommendations for safer treatments with less surgery and adjunctive measures but also improves survival rates and patient safety.

Indexed as

classificationprognosisriskstagingsurgerythyroid cancertnm

Identifiers

PMID40352024
PMCPMC12064280

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.